New and Novel Approaches in the Treatment of Moderate-to-Severe Atopic Dermatitis: Online CME Activity

About
Faculty
Learning Objectives
Intended Audience
Accreditation Statement
Credit Designation Statement
Disclosure
Disclaimer

New and Novel Approaches in the Treatment of Moderate-to- Severe Atopic Dermatitis

This CME Satellite Symposium was recorded at the 2021 Winter Clinical Dermatology Conference.

This activity is supported by an educational grant from Pfizer.

Alexandra Golant, MD FAAD

Faculty

Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Upon completion of this activity, the participant should be better able to:

Recognize the clinical features and biomarkers of Atopic Dermatitis (AD) to improve the diagnosis of adults with moderate-to-severe Atopic Dermatitis
Understand the benefits and risks of JAK Inhibitors for Atopic Dermatitis treatment
Develop an approach to how to integrate JAK inhibitors into your clinical armamentarium
Be able to tailor treatment plans for patients with AD

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nevada, Reno School of Medicine and Dermatology University. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONFLICTS OF INTEREST/DISCLOSURES

Alexandra K. Golant, MD

Consultant: Novartis, Abbvie, Lilly, UCB
Speakers’ Bureau or Honoraria: Sanofi Genzyme Regeneron, Ortho Dermatologics

[fc+358]

New and Novel Approaches in the Treatment of Moderate-to-Severe Atopic Dermatitis: Online CME Activity

New and Novel Approaches in the Treatment of Moderate-to- Severe Atopic DermatitisThis CME Satellite Symposium was recorded at the 2021 Winter Clinical Dermatology Conference. This activity is supported by an educational grant from Pfizer.

Alexandra Golant, MD FAAD

CONFLICTS OF INTEREST/DISCLOSURES

New and Novel Approaches in the Treatment of Moderate-to- Severe Atopic Dermatitis

This CME Satellite Symposium was recorded at the 2021 Winter Clinical Dermatology Conference.

This activity is supported by an educational grant from Pfizer.